diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-3596diaendo-3596Research ArticleСтатьиArticlesВлияние метформина на массу тела у больных сахарным диабетом 2 типа, получающих аналоги инсулинаEffects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatmentРоманцоваТатьяна ИвановнаRomantsovaTatiana Ivanovna-ДжавахишвилиТ ШDzhavakhishviliT Shtamrikojaf@yahoo.comРоикО ВRoikO V-ГБОУ ВПО Первый московский государственный медицинский университет им. И.М. Сеченова, МоскваI.M. Sechenov First Moscow State Medical University, Moscow201315032013161№1 (2013)4851Copyright © Романцова Т.И., Джавахишвили Т.Ш., Роик О.В., 20132013Романцова Т.И., Джавахишвили Т.Ш., Роик О.В.Romantsova T.I., Dzhavakhishvili T.S., Roik O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/3596сахарный диабет 2 типаинсулинотерапиямасса телааналоги инсулинаметформинdiabetes mellitus type 2insulin therapyinsulin analoguesmetforminReferencesAnderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analyses of clinical studies. J Am Coll Nutr. 2003 Oct;22(5):331–339.Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analyses of clinical studies. J Am Coll Nutr. 2003 Oct;22(5):331–339.Larger E. Weight gain and insulin treatment. Diabetes Metab. 2005 Sep;31(4 Pt 2):4S51–4S56.Larger E. Weight gain and insulin treatment. Diabetes Metab. 2005 Sep;31(4 Pt 2):4S51–4S56.Bagg W, Plank LD, Gamble G, Drury PL, Sharpe N, Braatvedt GD. The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. Diabetes Obes Metab. 2001 Dec;3(6):410–416.Bagg W, Plank LD, Gamble G, Drury PL, Sharpe N, Braatvedt GD. The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. Diabetes Obes Metab. 2001 Dec;3(6):410–416.Larger E, Rufat P, Dubois-Laforgue D, Ledoux S. Insulin and weight gain: myth or reality? Diabetes Metab. 2001 Nov;27(5 Pt 3):S23–27.Larger E, Rufat P, Dubois-Laforgue D, Ledoux S. Insulin and weight gain: myth or reality? Diabetes Metab. 2001 Nov;27(5 Pt 3):S23–27.Yki-Yarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001 Apr;24(4):758–767.Yki-Yarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001 Apr;24(4):758–767.Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia. 1999 Apr;42(4):406–412.Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia. 1999 Apr;42(4):406–412.Khan R. Weight gain and insulin therapy. Brit J Diabetes Vasc Dis. 2004;(4):264–267.Khan R. Weight gain and insulin therapy. Brit J Diabetes Vasc Dis. 2004;(4):264–267.Russel-Jones D, Khan R. Insulin-associated weight gain in diabetes – causes, effects and coping strategies. Diabetes Obes Metab. 2007 Nov;9(6):799–812.Russel-Jones D, Khan R. Insulin-associated weight gain in diabetes – causes, effects and coping strategies. Diabetes Obes Metab. 2007 Nov;9(6):799–812.Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulfonylureas in type 2 diabetes. Diabet Med. 2006 Feb;23(2):128–133.Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulfonylureas in type 2 diabetes. Diabet Med. 2006 Feb;23(2):128–133.Golay A. Metformin and body weight. Int J Obes (Lond). 2008 Jan;32(1):61–72.Golay A. Metformin and body weight. Int J Obes (Lond). 2008 Jan;32(1):61–72.Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type 11 noninsulin-dependent diabetes. Obes Res. 1998 Jan;6(1):47–53.Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type 11 noninsulin-dependent diabetes. Obes Res. 1998 Jan;6(1):47–53.Siram AT, Yanagisawa R, Skamagas M. Weight management in Type 2 Diabetes Mellitus. Mt Sinai J Med. 2010 Sep– Oct;77(5):533–548. doi: 10.1002/msj.20208.Siram AT, Yanagisawa R, Skamagas M. Weight management in Type 2 Diabetes Mellitus. Mt Sinai J Med. 2010 Sep– Oct;77(5):533–548. doi: 10.1002/msj.20208.Aubert G, Mansuy V, Voirol MJ, Pellerin L, Pralong FP. The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism. 2011 Mar;60(3):327–334. doi: 10.1016/j.metabol.2010.02.007.Aubert G, Mansuy V, Voirol MJ, Pellerin L, Pralong FP. The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism. 2011 Mar;60(3):327–334. doi: 10.1016/j.metabol.2010.02.007.Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B, Karlsson FA. Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab. 2007 Jul;9(4):483–489.Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B, Karlsson FA. Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab. 2007 Jul;9(4):483–489.Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995 Aug 31;333(9):550–554.Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995 Aug 31;333(9):550–554.Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006 Aug;29(8):1963–1972.Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006 Aug;29(8):1963–1972.
The authors declare that there are no conflicts of interest present.